Prognostic Value of CD44 Variant exon 6 Expression in Non-Small Cell Lung Cancer: a Meta-analysis

He, Jinlan; Qiu, Zhixin; Chen, Nian-Yong; Luo, Zhuojing; Chen, Bojiang; Liu, Weimin

doi:10.7314/apjcp.2014.15.16.6761

Cited by 39 publications

(28 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the association between CD44v6 and clinicopathological status remains controversial. According to the study performed by Zhao et al [15] , high CD44v6 expression was significantly associated with histopathological type and lymph node metastasis; however, there were no significant associations between CD44v6 and gender, tumor differentiation, or pathological stage. On the other hand, Luo et al [14] conducted a systematic review of CD44v6 expression and revealed that it was significantly associated with tumor differentiation, histological type, TNM stage, lymph node metastasis, and overall survival.…”

Section: Discussionmentioning

confidence: 93%

“…A multivariate analysis indicated that sCD44v6 level was an independent prognostic determinant for patients who underwent surgical resection for NSCLC. Although the multivariate analysis showed that there was no independent difference in immunochemical CD44v6 expression, a systematic review [14] , a meta-analysis [15] , and a recent report [33] support the finding that high CD44v6 expression is a prognostic factor for poor survival. In the present study of 261 patients, the multivariate analysis revealed that N factor and CD44v6 expression are independent prognostic factors (p = 0.0109 and 0.0485, respectively).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Immunohistochemical Expression and Serum Levels of CD44 as Prognostic Indicators in Patients with Non-Small Cell Lung Cancer

et al. 2016

View full text Add to dashboard Cite

Background/Objectives: CD44 is often expressed in various types of tumor cells and involved in a number of biological behaviors of malignancy. The present study focused on the clinical significance of the expression of CD44st and CD44v6 in non-small cell lung cancer (NSCLC). Methods: The cohort consisted of 261 consecutive patients who had undergone complete resection of NSCLC. CD44 expression was evaluated in surgical specimens by immunohistochemical staining. Serum CD44 levels were determined using a sandwich ELISA (enzyme-linked immunosorbent assay). Results: In the immunohistochemical analysis, significant correlations were observed between CD44 expression and clinicopathological factors such as the T factor, N factor, pathological stage, and histological type. The 5-year survival rates according to CD44v6 expression were 65.8 and 80.6% in the higher and lower expression groups, respectively (p = 0.0053). According to ELISA, the group with higher expression of serum CD44v6 also showed a significantly more unfavorable prognosis than the lower expression group (p = 0.014). According to multivariate analysis using these significant variables, serum CD44v6 level was found to be an independent prognostic factor (p = 0.048). Conclusions: CD44v6 overexpression and higher serum CD44v6 levels were found to be significantly unfavorable prognostic factors.

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Immunohistochemical Expression and Serum Levels of CD44 as Prognostic Indicators in Patients with Non-Small Cell Lung Cancer

et al. 2016

View full text Add to dashboard Cite

show abstract

“…COX-2 expression promotes proliferation, angiogenesis and lymphangiogenesis within tumor cells, as well as promoting tumor invasion and metastasis (3)(4)(5). Cluster of differentiation 44 variant 6 (CD44v6) is a splice variant of CD44, and its expression may alter the composition and functioning of adhesion molecules on the tumor cell surface, thereby contributing to the development of metastatic potential in tumor cells (6,7). Matrix metalloproteinase-2 (MMP-2) is the most widely distributed member of the MMP family, and is able to degrade the extracellular matrix (ECM) and basement membrane, thus participating in physiological and pathological processes including tumor progression (8,9).…”

Section: Introductionmentioning

confidence: 99%

Impact and mechanism of non-steroidal anti-inflammatory drugs combined with chemotherapeutic drugs on human lung cancer-nude mouse transplanted tumors

Sun

Chen

2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. The present study aimed to investigate the impact of indomethacin treatment combined with oxaliplatin treatment on the expression of cluster of differentiation 44 variant 6 (CD44v6), matrix metalloproteinase-2 (MMP-2) and survivin in human lung cancer-nude mouse transplanted tumors. The human lung adenocarcinoma (A549)-nude mouse transplanted tumor model was established, and the mice were divided into a control group, an indomethacin treatment group, an oxaliplatin treatment group and an indomethacin-oxaliplatin combination treatment group. The tumor inhibition rate was calculated following sacrificing of the mice. Immunohistochemical staining and fluorescence reverse transcription-quantitative polymerase chain reaction were utilized to detect the protein and messenger (m)RNA expression of CD44v6, MMP-2 and survivin. The tumor inhibition rates of the indomethacin group, the oxaliplatin group and the combination group were 26.67, 47.70 and 68.88%, respectively. The protein and mRNA expression levels of CD44v6, MMP-2 and survivin in the transplanted tumors of each treatment group were reduced compared with the control group (P<0.05), and those of the combination group were lower compared with the single-drug treatment groups (P<0.05). Survivin and MMP-2, MMP-2 and CD44v6, and MMP-2 and CD44v6 all exhibited linear positive correlation. The present study provides evidence that the administration of indomethacin alone, or in combination with oxaliplatin, may significantly inhibit the growth of lung cancer-nude mouse transplanted tumors and the expression of CD44v6, MMP-2 and survivin inside the tumor. The combination of non-steroidal anti-inflammatory drugs with chemotherapeutic drugs may improve the antitumor effects.

show abstract

“…The expression of CD44 in metastatic ovarian cancer cells was significantly higher than that in primary ovarian cancer cells [28]. CD44 has been shown to be associated with tumor migration and metastasis in colon cancer and breast cancers，and could be used as a prognostic indicator in lung cancer [29][30][31]. CD44 is the major cellular receptor for HA and in association with HA, CD44 has a certain impact on the activation of cell-survival antiapoptotic proteins, consequently resulting in tumor cell proliferation and tumorigenesis in hepatocellular carcinoma and lung cancers [6,32,33].…”

Section: Discussionmentioning

confidence: 99%

Targeting CD44 by CRISPR-Cas9 in Multi-Drug Resistant Osteosarcoma Cells

Zheng

Wan

Nur

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Drug resistance is the main difficulty for the current treatment for osteosarcoma. Cluster of differentiation 44 (CD44) is a receptor for hyaluronic acid (HA) and HA-binding has been proven to participate in various biological tumor activities, including tumor progression, metastasis and drug resistance. In this study, we aimed to determine the effects of CD44 on migration, invasion, proliferation, and the drug-sensitivity of osteosarcoma. Methods: 96 human osteosarcoma tissues from 56 patients were collected to evaluate the expression of CD44 in osteosarcoma tissue by immunohistochemistry. CRISPR-Cas9 system was used to specifically silence CD44 in drug-resistant cell lines (KHOSR2 and U-2OSR2). The migration and invasion activities of cells was demonstrated by wound healing and transwell invasion assay. The proliferation speed of the cells was detected under 3D cell culture condition. Drug resistance of cells was detected by MTT and drug uptake assay. Results: The immunohistochemistry results demonstrated that a high level of CD44 may predict poor survival and higher potential of metastasis, recurrence and drug resistance in patients with osteosarcoma. After knocking-out of CD44 by the CRISPR-Cas9 system, not only the migration and invasion activities of osteosarcoma cells were significantly inhibited, but the drug sensitivity was also enhanced. Conclusion: CD44 silencing could inhibit the development of osteosarcoma migration, invasion, proliferation and ameliorate drug resistance to current treatment in osteosarcoma. This study applies new strategy to target CD44, which may improve the prognosis of osteosarcoma.

show abstract

Prognostic Value of CD44 Variant exon 6 Expression in Non-Small Cell Lung Cancer: a Meta-analysis

Cited by 39 publications

References 27 publications

Immunohistochemical Expression and Serum Levels of CD44 as Prognostic Indicators in Patients with Non-Small Cell Lung Cancer

Immunohistochemical Expression and Serum Levels of CD44 as Prognostic Indicators in Patients with Non-Small Cell Lung Cancer

Impact and mechanism of non-steroidal anti-inflammatory drugs combined with chemotherapeutic drugs on human lung cancer-nude mouse transplanted tumors

Targeting CD44 by CRISPR-Cas9 in Multi-Drug Resistant Osteosarcoma Cells

Contact Info

Product

Resources

About